Keros Therapeutics, Inc. (KROS)
↓ Download CSV- Sector Manufacturing
- Fiscal year ends Dec 31
In fiscal 2025, Keros Therapeutics, Inc. reported revenue of $244.06M, up 6775.0% from the prior year. The company was profitable, with a net margin of 35.7%. It held $338.02M in total assets against $34.89M in total liabilities.
Key ratios (FY2025)
27.7%
Operating margin
35.7%
Net margin
28.7%
Return on equity
+6775.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $244.06M | $3.55M | $151.0K | $0 | $20.10M | $0 | $10.00M | — |
| Operating Income | $67.57M | -$210.83M | -$169.94M | -$114.79M | -$56.37M | -$46.66M | -$10.56M | — |
| Net Income | $87.01M | -$187.35M | -$152.99M | -$104.68M | -$58.74M | -$45.36M | -$12.34M | — |
| EPS (Diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 | $-2.93 | — | — |
| Total Assets | $338.02M | $615.89M | $370.02M | $306.78M | $255.25M | $269.44M | $10.96M | — |
| Total Liabilities | $34.89M | $44.33M | $37.81M | $29.36M | $12.08M | $7.72M | $10.46M | — |
| Shareholders' Equity | $303.13M | $571.55M | $332.21M | $277.42M | $243.17M | $261.72M | -$19.45M | -$7.18M |
| Cash & Equivalents | $287.42M | $559.93M | $331.15M | $279.05M | $230.04M | $265.88M | $7.02M | — |
| Operating Cash Flow | $107.50M | -$160.87M | -$124.51M | -$70.06M | -$62.15M | -$36.89M | -$16.00M | — |
| Capital Expenditures | $1.55M | $1.93M | $2.46M | $1.24M | $1.02M | $294.0K | $271.0K | — |
| Shares Outstanding | 19.54M | 40.55M | 31.84M | 27.54M | 23.97M | 23.19M | 2.43M | — |